肺动脉高压患者感染COVID-19的全国前瞻性队列研究
该研究在法国肺动脉高压网络中前瞻性纳入2020年2月1日至2021年4月30日期间感染COVID-19的成人毛细血管前肺动脉高压患者,描述其临床特征、管理及结局。共211例患者,总体死亡率为24.6%,住院患者院内死亡率为41.3%,死亡者年龄更大、合并症更多且肺动脉高压更严重。
要点
- 毛细血管前肺动脉高压患者感染COVID-19后院内死亡率高(41.3%)。
- 死亡者年龄更大、男性更多、合并症更多且肺动脉高压更严重。
- 肺动脉高压靶向治疗在存活者与死亡者间使用情况相似。
核心结论
- 毛细血管前肺动脉高压患者感染COVID-19与高院内死亡率相关。
- 重症COVID-19的典型危险因素及肺动脉高压严重程度与该人群死亡率相关。
研究设计与样本
- 法国肺动脉高压网络前瞻性队列研究,纳入2020年2月1日至2021年4月30日期间感染COVID-19的成人毛细血管前肺动脉高压患者。
- 共纳入211例患者,包括123例肺动脉高压、47例慢性血栓栓塞性肺动脉高压和41例其他类型肺动脉高压。
主要发现
- 40.3%的患者为门诊管理,32.2%住院于普通病房,27.5%入住ICU。
- 住院患者(n=126)中54.0%接受糖皮质激素治疗,37.3%接受高流量氧疗,11.1%接受有创通气。
- 右心衰竭和急性肾衰竭分别发生于30.2%和19.8%的患者。
- 死亡者年龄更大、男性更多、合并症(糖尿病、慢性呼吸系统疾病、系统性高血压、慢性心脏病和/或慢性肾衰竭)更多,且COVID-19诊断前最近一次评估的肺动脉高压更严重(功能分级和6分钟步行距离,均P<0.05)。
临床怎么用
- 对合并COVID-19的毛细血管前肺动脉高压患者应警惕高院内死亡风险,尤其对高龄、男性、合并症多及肺动脉高压严重者加强监护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with pulmonary endothelial dysfunction. There are limited data available on the outcomes of coronavirus disease (COVID-19) in patients with pulmonary hypertension (PH), a disease characterized by pulmonary endothelial dysfunction. Objectives: To describe characteristics and outcomes of patients with precapillary PH and COVID-19. Methods: We prospectively collected characteristics, management, and outcomes of adult patients with precapillary PH in the French PH network who had COVID-19 between February 1, 2020, and April 30, 2021. Clinical, functional, and hemodynamic characteristics of PH before COVID-19 were collected from the French PH registry. Measurements and Main Results: A total of 211 patients with PH (including 123 with pulmonary arterial hypertension, 47 with chronic thromboembolic PH, and 41 with other types of PH) experienced COVID-19, and 40.3% of them were outpatients, 32.2% were hospitalized in a conventional ward, and 27.5% were in an ICU. Among hospitalized patients (n = 126), 54.0% received corticosteroids, 37.3% high-flow oxygen, and 11.1% invasive ventilation. Right ventricular and acute renal failure occurred in 30.2% and 19.8% of patients, respectively. Fifty-two patients (all hospitalized) died from COVID-19. Overall mortality was 24.6% (95% CI [confidence interval], 18.8-30.5) and in-hospital mortality 41.3% (95% CI, 32.7-49.9). Nonsurvivors were significantly older, more frequently male and suffering comorbidities (diabetes, chronic respiratory diseases, systemic hypertension, chronic cardiac diseases, and/or chronic renal failure), and had more severe PH at their most recent evaluation preceding COVID-19 diagnosis (in terms of functional class and 6-minute-walk distance; all P < 0.05). Use of pulmonary arterial hypertension therapy was similar between survivors and nonsurvivors. Conclusions: COVID-19 in patients with precapillary PH was associated with a high in-hospital mortality. The typical risk factors for severe COVID-19 and severity of PH were associated with mortality in this population.
引用
- Montani D, Certain MC, Weatherald J, et al. COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. Am J Respir Crit Care Med. 2022. PMID: 35549842. doi:10.1164/rccm.202112-2761OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。